Nvidia among investors in xAI’s $20 bln capital raise- Bloomberg
On Wednesday, UBS analysts reaffirmed a Buy rating for CME Group (NASDAQ:CME) stock, maintaining a price target of $305.00. Currently trading at $279.01 with a market capitalization of $100.6 billion, CME’s May performance metrics indicated a moderation in futures volume quicker than anticipated. According to InvestingPro data, the stock is trading near its 52-week high of $290.79.
UBS analysts adjusted their earnings per share (EPS) estimate for the second quarter of 2025, reducing it to $2.95 from a previous $2.99. This adjustment comes in light of the recent trends observed in futures pricing. Notably, InvestingPro reports that 12 analysts have revised their earnings upwards for the upcoming period, with price targets ranging from $211 to $305. Despite this revision, the analysts continue to forecast a 20% growth in futures volume for the second quarter and an 8% increase for the entire year of 2025.
In contrast to the slight downturn in futures volume, UBS analysts have raised their projections for cash markets. Strong activity levels were reported at BrokerTec and EBS, contributing to a positive outlook in this area. This aligns with CME’s robust revenue growth of 11.73% over the last twelve months.
The analysts expressed continued optimism about CME Group stock, citing factors such as elevated interest rates and ongoing geopolitical and macroeconomic uncertainties. They noted that the stock remains undervalued compared to its historical range relative to the S&P 500.
CME Group, a major player in the financial markets, continues to navigate the dynamic economic landscape, with UBS analysts maintaining a favorable outlook for its stock performance.
In other recent news, CME Group reported a record average daily volume (ADV) for May 2025, with 28.9 million contracts traded, reflecting an 11% increase from the previous year. This growth was observed across various asset classes, including interest rates, metals, and cryptocurrencies. The company also announced the upcoming launch of four new cryptocurrency reference rates and real-time indices, expanding its offerings to include Arbitrum, Ondo, NEAR, and Sui. This expansion aims to provide transparent pricing data for emerging digital assets.
Additionally, Erste Group downgraded its rating on CME Group stock from Buy to Hold, citing expectations of decelerating growth in turnover and net profit. In contrast, UBS maintained its Buy rating and set a price target of $305.00, highlighting the increasing participation of retail investors and the firm’s strong competitive position. Barclays (LON:BARC) kept its Equalweight rating, with a price target of $283.00, noting mixed revenue trends from BrokerTec and EBS. These developments reflect a dynamic period for CME Group, with significant trading volume achievements and varied analyst opinions on its financial prospects.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.